| #1 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition | 2026-04-28 |
| #2 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-Amplifying Iron-Ferroptosis-Edema Cascade Post-Cardiac Arrest | 2026-04-28 |
| #3 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | Glymphatic-Mediated Tau Clearance Dysfunction | 2026-04-28 |
| #4 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection | 2026-04-28 |
| #5 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | H6: Aberrant eIF2α Phosphorylation Creates Stalled Translation State | 2026-04-28 |
| #6 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling | 2026-04-28 |
| #7 | PD Dopaminergic Neuron Expression Signature | 1.0000 | forge:hypothesis_eval | TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance | 2026-04-28 |
| #8 | ALS Motor Neuron Survival Gene Prediction | 0.9996 | forge:hypothesis_eval | p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methylation Balance | 2026-04-28 |
| #9 | ALS Motor Neuron Survival Gene Prediction | 0.9996 | forge:hypothesis_eval | Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse | 2026-04-28 |
| #10 | ALS Motor Neuron Survival Gene Prediction | 0.9996 | forge:hypothesis_eval | TDP-43 RNA-proteostasis failure across ALS, FTD, and AD/LATE | 2026-04-28 |
| #11 | ALS Motor Neuron Survival Gene Prediction | 0.9996 | forge:hypothesis_eval | Hypothesis 7: SST-SST1R/Gamma Entrainment-Enhanced Astrocyte Secretome | 2026-04-28 |
| #12 | Glymphatic Clearance Biomarker Panel | 0.9922 | forge:hypothesis_eval | Glymphatic-Mediated Tau Clearance Dysfunction | 2026-04-28 |
| #13 | Glymphatic Clearance Biomarker Panel | 0.9842 | forge:hypothesis_eval | Plasma NfL Elevation Secondary to BBB-Associated Transport Dysfunction Enables Longitudinal Neurodegeneration Tracking | 2026-04-28 |
| #14 | ALS Motor Neuron Survival Gene Prediction | 0.9678 | forge:hypothesis_eval | TBK1 Loss Locks Microglia in an Aged/Senescent Transcriptional State, Fueling ALS-Associated SASP | 2026-04-28 |
| #15 | Glymphatic Clearance Biomarker Panel | 0.9601 | forge:hypothesis_eval | Elevated CSF/Serum Albumin Quotient Predicts Neurodegeneration Progression Independent of Age | 2026-04-28 |
| #16 | Glymphatic Clearance Biomarker Panel | 0.9432 | forge:hypothesis_eval | Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration | 2026-04-28 |
| #17 | Glymphatic Clearance Biomarker Panel | 0.9361 | forge:hypothesis_eval | Prime Editing Precision Correction of APOE4 to APOE3 in Microglia | 2026-04-28 |
| #18 | ALS Motor Neuron Survival Gene Prediction | 0.9322 | forge:hypothesis_eval | RBM45 Liquid-Liquid Phase Separation Dominance Hijacks RNA Processing Condensates Toward Pathological Aggregation in ALS | 2026-04-28 |
| #19 | Glymphatic Clearance Biomarker Panel | 0.9283 | forge:hypothesis_eval | TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease | 2026-04-28 |
| #20 | Glymphatic Clearance Biomarker Panel | 0.9283 | forge:hypothesis_eval | ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia | 2026-04-28 |